ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "No pain, no gain: Ozempic’s quest for market share"
Episode Synopsis
The shock success of GLP-1 treatments for obesity carries massive implications for wealthy societies and manufacturers Novo Nordisk and Eli Lilly alike. In this week’s Viewsroom podcast, Breakingviews columnists discuss how this would-be jackpot has companies running to keep up.
Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.
Learn more about your ad choices. Visit megaphone.fm/adchoices
More episodes of the podcast Viewsroom
A Ukraine deal would be peace in name only
04/12/2025
Britain’s fiscal ship lost at sea
20/11/2025
China’s low-cost AI offers competitive edge
06/11/2025
Necessity will birth a US-China trade truce
23/10/2025
In God we trust